This is I have found using grok deeper search. This is just the conclusion but should answer to at least some of your questions
Conclusion
As of July 30, 2025, Nanobot Biosciences appears to be the most relevant company developing nanobots tested in mice via the bloodstream for cancer treatment, leveraging DNA origami technology to target and kill cancer cells while sparing healthy ones. Nanobots Therapeutics, while a significant player in nanobot-based cancer therapy, primarily focuses on bladder cancer with direct administration. Both companies represent the cutting edge of this field, with potential for future advancements in clinical applications.
Table: Summary of Key Companies and Their Technologies
| Company | Founded | Location | Technology | Testing in Mice (Bloodstream) | Primary Focus | Stage (2025) |
|---|
| Nanobot Biosciences | 2019 | Arizona, USA (ASU spin-off) | DNA origami nanobots with thrombin | Yes, via bloodstream | General cancer treatment | Preclinical |
| Nanobots Therapeutics | 2023 | Barcelona, Spain (IBEC/ICREA) | Urease-powered nanobots | No, direct bladder administration | Bladder cancer | Preclinical |
This table summarizes the key attributes of the identified companies, highlighting their relevance to the query and current development stage.
(20min delay)